Download
12931_2024_Article_3056.pdf 2,01MB
WeightNameValue
1000 Titel
  • Assessing the comparative effects of interventions in COPD: a tutorial on network meta-analysis for clinicians
1000 Autor/in
  1. Haeussler, Katrin |
  2. Ismaila, Afisi |
  3. Malmenäs, Mia |
  4. Noorduyn, Stephen |
  5. Green, Nathan |
  6. Compton, Christopher |
  7. Thabane, Lehana |
  8. Vogelmeier, Claus |
  9. Halpin, David M.G. |
1000 Verlag
  • BioMed Central
1000 Erscheinungsjahr 2024
1000 Publikationstyp
  1. Artikel |
1000 Online veröffentlicht
  • 2024-12-21
1000 Erschienen in
1000 Quellenangabe
  • 25(1):438
1000 Copyrightjahr
  • 2024
1000 Lizenz
1000 Verlagsversion
  • https://doi.org/10.1186/s12931-024-03056-x |
  • https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11663313/ |
1000 Publikationsstatus
1000 Begutachtungsstatus
1000 Sprache der Publikation
1000 Abstract/Summary
  • <jats:title>Abstract</jats:title><jats:p>To optimize patient outcomes, healthcare decisions should be based on the most up-to-date high-quality evidence. Randomized controlled trials (RCTs) are vital for demonstrating the efficacy of interventions; however, information on how an intervention compares to already available treatments and/or fits into treatment algorithms is sometimes limited. Although different therapeutic classes are available for the treatment of chronic obstructive pulmonary disease (COPD), assessing the relative efficacy of these treatments is challenging. Synthesizing evidence from multiple RCTs via meta-analysis can help provide a comprehensive assessment of all available evidence and a “global summary” of findings. Pairwise meta-analysis is a well-established method that can be used if two treatments have previously been examined in head-to-head clinical trials. However, for some comparisons, no head-to-head studies are available, for example the efficacy of single-inhaler triple therapies for the treatment of COPD. In such cases, network meta-analysis (NMA) can be used, to indirectly compare treatments by assessing their effects relative to a common comparator using data from multiple studies. However, incorrect choice or application of methods can hinder interpretation of findings or lead to invalid summary estimates. As such, the use of the GRADE reporting framework is an essential step to assess the certainty of the evidence. With an increasing reliance on NMAs to inform clinical decisions, it is now particularly important that healthcare professionals understand the appropriate usage of different methods of NMA and critically appraise published evidence when informing their clinical decisions. This review provides an overview of NMA as a method for evidence synthesis within the field of COPD pharmacotherapy. We discuss key considerations when conducting an NMA and interpreting NMA outputs, and provide guidance on the most appropriate methodology for the data available and potential implications of the incorrect application of methods. We conclude with a simple illustrative example of NMA methodologies using simulated data, demonstrating that when applied correctly, the outcome of the analysis should be similar regardless of the methodology chosen.</jats:p>
1000 Sacherschließung
lokal Bucher ITC
lokal Chronic obstructive pulmonary disease
lokal Humans [MeSH]
lokal Treatment Outcome [MeSH]
lokal GRADE
lokal Single-inhaler triple therapy
lokal Randomized Controlled Trials as Topic/methods [MeSH]
lokal Network Meta-Analysis as Topic [MeSH]
lokal Pulmonary Disease, Chronic Obstructive/drug therapy [MeSH]
lokal Pulmonary Disease, Chronic Obstructive/therapy [MeSH]
lokal Randomized controlled trials
lokal Bayesian
lokal Network meta-analysis
lokal Head-to-head comparison
lokal Pulmonary Disease, Chronic Obstructive/diagnosis [MeSH]
lokal Frequentist
lokal Review
lokal Indirect treatment comparison
1000 Fächerklassifikation (DDC)
1000 Liste der Beteiligten
  1. https://orcid.org/0000-0002-3236-2028|https://orcid.org/0000-0002-2876-8308|https://orcid.org/0000-0002-2625-9198|https://orcid.org/0000-0002-5936-5579|https://orcid.org/0000-0003-2745-1736|https://orcid.org/0000-0002-7564-5343|https://orcid.org/0000-0003-0355-9734|https://orcid.org/0000-0002-9798-2527|https://orcid.org/0000-0003-2009-4406
1000 Hinweis
  • DeepGreen-ID: da9bb8dd3bdf480684f245bfba525ab2 ; metadata provieded by: DeepGreen (https://www.oa-deepgreen.de/api/v1/), LIVIVO search scope life sciences (http://z3950.zbmed.de:6210/livivo), Crossref Unified Resource API (https://api.crossref.org/swagger-ui/index.html), to.science.api (https://frl.publisso.de/), ZDB JSON-API (beta) (https://zeitschriftendatenbank.de/api/), lobid - Dateninfrastruktur für Bibliotheken (https://lobid.org/resources/search)
1000 Label
1000 Dateien
1000 Objektart article
1000 Beschrieben durch
1000 @id frl:6491528.rdf
1000 Erstellt am 2025-02-03T14:44:59.697+0100
1000 Erstellt von 322
1000 beschreibt frl:6491528
1000 Zuletzt bearbeitet 2025-07-30T08:32:53.241+0200
1000 Objekt bearb. Wed Jul 30 08:32:53 CEST 2025
1000 Vgl. frl:6491528
1000 Oai Id
  1. oai:frl.publisso.de:frl:6491528 |
1000 Sichtbarkeit Metadaten public
1000 Sichtbarkeit Daten public
1000 Gegenstand von

View source